Given the multifaceted nature of ADCs, developers should have an integrated analytical toolkit. Three complementary approaches dominate the current landscape: Ligand Binding Assays (LBA): Ideal for ...

- Lantern will evaluate and potentially develop ADC programs with novel patent protected linkers, drug payloads and conjugation processes from Califia that have demonstrated enhanced, highly targeted ...

As the oncology landscape evolves, antibody-drug conjugates (ADCs) have emerged as one of the most promising modalities in ...

In this free webinar, explore recent developments in next-generation antibody-drug conjugates (ADCs) and emerging strategies in ADC conjugation and linker design. Attendees will learn how ...

Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.

Lonza is responsible for manufacturing proprietary tech components and Sidewinder for ADC, R&D, manufacturing, and commercialization.

ST. LOUIS, Oct. 14, 2013 -- Sigma-Aldrich Corporation's (SIAL) custom manufacturing services business unit, SAFC® Commercial (www.sigma-aldrich.com/safc), is ...

The Antibody Drug Conjugate (ADC) Market expanded from USD 6.48 billion in 2024 to USD 7.55 billion in 2025 and is projected to grow at a CAGR of 16.24%, reaching USD 15.99 billion by 2030. This ...

As the proportion of clinically site-specific ADCs increases, the abundance of novel conjugation technologies diversifies, and the linker chemistry toolkit is expanded, investments in linker and ...

AMSTERDAM--(BUSINESS WIRE)--Synaffix BV announced today that ADC Therapeutics has triggered a second target-specific license under their Commercial License Agreement dated October 2016, to develop an ...